The Try Guys Get Prostate Exams
For men who are weighing the pros and cons of prostate cancer screening, a new study strengthens the evidence that testing can reduce deaths from this cancer, something two earlier large landmark clinical trials appeared to reach different conclusions about.
The findings do not resolve many of the questions that remain about Prostatamassagers Test cancer screening, since routine testing can lead to unneeded and potentially harmful treatments in men who do not need it. But it provides more information that experts can use to assess the benefits and risks of screening.
One of the earlier trials, conducted in Europefound that screening reduced deaths from prostate cancer by 21 percent, though it led many men down a bumpy road toward harmful or even unnecessary interventions.
The other trial, based in the United Statesfound no difference in death rates between men who were randomly assigned to screening and those who were not. Both reports Prostatamassagers Test published in in the New England Journal of Medicine. For the new paper, Prostatamassagers Test Monday in Annals of Internal Medicinea broad consortium of scientists, including some of the investigators in the original studies, reanalyzed the data from the two trials using three different mathematical models.
When they made a rigorous comparison Prostatamassagers Test death rates among men who had actually undergone screening and men who had received no screening, the researchers concluded that screening tests reduced prostate cancer Prostatamassagers Test by 25 Prostatamassagers Test 32 percent. The reduction was primarily a result of the earlier detection of cancer, the researchers said. About three-quarters of the men in the group that were in the comparison group that was not assigned to screening in the trial were still tested as part of their regular medical care, she said.
Etzioni said. Several investigators from the earlier trials, who made their records available for the new analysis, are also authors on the new paper, and scientists involved in the American trial, which goes by the acronym PLCO, said the Prostatamassagers Test was an important contribution.
Screening for prostate cancer Prostatamassagers Test typically done using a blood test that measures levels of a protein released by the prostate gland called prostate-specific antigen, or PSA, which may indicate the presence of prostate cancer when elevated.
But increased levels can also be caused by less serious medical conditions, like inflammation. While prostate cancer is one of the most common cancers affecting men and it Prostatamassagers Test be aggressive, many men have a slow-growing form of the disease Prostatamassagers Test will likely never become life-threatening, and would not even know about it if not Prostatamassagers Test screening. More patients with these low-grade cancers are now being closely monitored by doctors instead of undergoing surgery and radiation, treatments that can lead to serious complications such as incontinence and impotence.
The aim of monitoring, or active Prostatamassagers Test as it is called, is to prevent unneeded treatment, said Dr. Etzioni, who does research on the harms of screening as well. In its most recent draft of recommendations issued in April, the United States Preventive Services Task Force urged older men to talk to their doctors about the benefits and risks of prostate cancer Prostatamassagers Test and make an individual decision that is right for them.
The task force could massage the recommendation further over the next few months before issuing a final version. Andrew J. Vickers, an attending research methodologist at Memorial Sloan Kettering Cancer Center, who wrote an editorial accompanying the new papersaid in an interview that there really is no doubt that PSA screening can curb the death rate from prostate cancer.
Vickers said. Prostatamassagers Test of screening say the new analysis does not change much in the calculation of Prostatamassagers Test versus benefits Prostatamassagers Test screening. Only 3 percent of men die of prostate cancer, so the benefit of screening, in the number of prostate cancer Prostatamassagers Test averted, is small in absolute terms.
Some critics of screening expressed skepticism about the new analysis, however. Lin, a member of committee that has been reviewing the United States Preventive Services Task Force recommendations for the American Academy of Family Physicians, which advises against routine prostate cancer screening. Men who have a family history of prostate cancer or any symptoms of the disease should be screened, experts say, as should older African-American men, who are at higher risk for prostate cancer.
For other men aged 55 to 69, the trade-offs between potential benefits and harms of screening are a close call. The Preventive Services Task Force recommends men 70 and older forgo screening. Gilbert Welch, professor of medicine at the Dartmouth Institute, who says he believes very few men are helped by the test.